Rx Medicare

Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) announced that Professor Dr. Otto Haller from the Department of Virology, Freiburg University, Germany and Professor Dr. Oliver Planz from the Friedrich Loeffler Institute, Tubingen, Germany gave two separate presentations on the efficacy of interferon to combat influenza. The presentations were made at the National Symposium for Zoonosis Research, held in Berlin, Germany October 7-8, 2009. Dr.

Read More…

Related Posts

• Amarillo Biosciences Announces Australian Phase 2 Oral Interferon Clinical Trial Indicates Benefit In Preventing Influenza-Like Illness In Seniors
• Amarillo Biosciences Announces Completion Of Screening Process For Influenza Study In Australia
• Amarillo Biosciences Comments On New Findings Of H1N1 In Animals And Potential Effect On Human Infections
• A Call For Research On The Emerging Influenza Pandemic
• Wiley-Blackwell Makes Research Publications On Influenza A (H1N1) Freely Available
• AmpVacs A Broadly Protective Synthetic Influenza A Vaccine
• Dog Flu: Canine Influenza (CIV) In Dogs
• Dry Winters Linked To Seasonal Outbreaks Of Influenza
• Diagnostic Hybrids Receives FDA Emergency Use Authorization For D3 Ultra 2009 H1N1 Influenza A Virus ID Kit
• Poor Evidence For Effectiveness Of Influenza Vaccines In Elderly
• Mandatory Policy Boosts Influenza Vaccination Rate Among Health Care Workers
• AAMC Commends The President For Supporting NIH Research And Medicare
• A(H1N1) Influenza Pandemic: Sanofi Pasteur’s Global Response
• European Medicines Agency Updates On Pandemic Influenza
• Get Vaccinated For Influenza; It’s Not Too Late – Alabama Department of Public Health

Tags: amarillo, biosciences, combat, efficacy, influenza, interferon, research, supporting

This entry was posted on Sunday, October 11th, 2009 at 10:10 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.